Dialysis industry news

Stories from the dialysis comunity across the globe.



Zacks Short Term Rating on Fresenius Medical Care Corporation (NYSE:FMS) - Insider Trading Report PDF Print

Fresenius Medical Care Corporation (NYSE:FMS) has received a hold rating for the short term, according to the latest rank of 3 from research firm, Zacks. The shares could manage an average rating of 2.67 from 9 analysts. As per the latest data, 1 analysts has given a sell rating on the shares of the company. 2 market experts have marked it as a strong buy. 6 analysts have rated the company at hold.

Fresenius Medical Care Corporation (NYSE:FMS): 5 analysts have set the short term price target of Fresenius Medical Care Corporation (NYSE:FMS) at $43.61. The standard deviation of short term price target has been estimated at $5.04, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 50 and $39 respectively. Many analysts have commented on the company rating. In a research note released to the investors, HSBC upgrades its rating on Fresenius Medical Care Corporation (NYSE:FMS). Investors must note that the brokerage house has a Neutral rating on the shares of the company. Previously, the company had a rating of Underweight. The rating by the firm was issued on February 27, 2015. Fresenius Medical Care Corporation (NYSE:FMS) rose 0.51% or 0.21 points on Monday and made its way into the gainers of the day. After trading began at $41.4 the stock was seen hitting $41.78 as a peak level and $41.37 as the lowest level. The stock ended up at $41.77. The daily volume was measured at 1,101,268 shares. The 52-week high of the share price is $44.34 and the 52-week low is $32.4. The company has a market cap of $26,081 million. Institutional Investors own 2% of Company shares. During last 3 month period, 1.24% of total institutional ownership has changed in the company shares. Fresenius Medical Care AG & Co KGaA is a Germany-based kidney dialysis company that operates in the fields of dialysis care and dialysis products for the treatment of end-stage renal disease (ESRD). Its dialysis business is vertically integrated and offers products and services for the entire dialysis value chain, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. The Company offers two types of dialysis treatment: Hemodialysis (HD), where the machine controls the blood from the patient through a special filter, the dialyzer, and Peritoneal Dialysis (PD), where the patients peritoneum is used as a dialyzing membrane. Its dialysis product portfolio includes chronic hemodialysis, home dialysis, renal pharmaceuticals, acute therapy, liver support, therapeutic apheresis, therapy support and water technology, among others. In addition, the Company sells dialysis products to other dialysis service providers.

...

 
Zacks Short Term Rating on Rockwell Medical, Inc. (NASDAQ:RMTI) - OTC Outlook PDF Print

As many as 5 brokerage firms have rated Rockwell Medical, Inc. (NASDAQ:RMTI) at 2.2. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. 1 analysts have rated it as strong sell. The stock garnered a place in the hold list of 1 stock Analysts. 3 analysts rated the company as a strong buy.

Rockwell Medical, Inc. (NASDAQ:RMTI): The stock price is expected to reach $ 16.6 in the short term. The number of analysts agreeing with this consensus is 5. The higher estimate for the short term price target is at $26 while the lower estimate is at $4. The standard deviation of the price stands at $7.99. Many analysts have commented on the company rating. In a research note released to the investors, Bank of America reinstates its rating on Rockwell Medical, Inc. (NASDAQ:RMTI).The analysts at the brokerage house have a current rating of Neutral on the shares. The rating by the firm was issued on July 8, 2015. Rockwell Medical, Inc. (NASDAQ:RMTI) rose 0.86% or 0.12 points on Monday and made its way into the gainers of the day. After trading began at $14.15 the stock was seen hitting $14.53 as a peak level and $13.98 as the lowest level. The stock ended up at $14.09. The daily volume was measured at 533,528 shares. The 52-week high of the share price is $18.8999 and the 52-week low is $8.095. The company has a market cap of $708 million. Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0% in the total insider ownership. Institutional Investors own 34.4% of Company shares. During last 3 month period, 25.61% of total institutional ownership has changed in the company shares. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...

 
Letter: Dialysis in Gunnedah, it can be achieved - Namoi Valley Independent PDF Print

Scott Hawkins, of Salisbury, Queensland, writes:

Scott Hawkins, of Salisbury, Queensland, writes:

I am a home haemo-dialysis patient in Brisbane. I studied nursing in Armidale and have fond memories of practicals at Tamworth Base Hospital.

I have been dialysing at home for six years and spend a day each month in the unit for transplant bloods etc. 

I don’t understand why it would be so expensive to put a dialysis machine into Gunnedah hospital. A Fresenius or Gambro can be had for under $20,000. The companies will generally train a few nurses and they don’t require dedicated staff, although that is preferable. 

During the 90s, Manning Base Hospital (Taree) had one machine which they pulled out for holiday patients and staffed with a nurse who normally worked in A&E and ICU.

It can certainly be done.  I have dialysed in country towns up and down the east coast from Ballarat to Cairns, whilst on holidays. I have a grey nomad friend who has dialysed in Cairns, Bundaberg, Hobart, Launceston, Ballarat, Darwin, Hervey Bay and many more. 

Unfortunately, the bush rarely gets its share. The smaller country hospitals tend to get forgotten, however it can be achieved!

If you are looking for inspiration, google Western Desert dialysis – $15.3million of federal money has just been granted to an old friend of mine who also studied nursing in Armidale.

This money is to be spent on the very worthwhile project of dialysing Aboriginal people on their own land. 

Also, google nXstage for a different perspective on the problem. I know they are keen to gain access in Australia and their machines are currently used in Cairns both in-centre and in places like Palm Island. These machines are portable and are available for holiday use for patients in Brisbane.

I think people in the bush need to think about how they vote and make their seats as marginal as possible so they get the attention they deserve. You need to be able to replicate what Wilke has done in Hobart. That is never going to happen whilst the conservatives have you lock stock, unfortunate but true!

Good luck Gunnedah, you should have a machine in your hospital. Make Barnaby work for his money and I will see you for holiday dialysis soon. (I hope!)

...

 
Mild hypothermia improves transplantation outcomes - Nature.com PDF Print
Nature.com
The induction of therapeutic hypothermia in deceased organ donors significantly reduces delayed graft function in kidney transplant recipients, according to new findings. “Our research shows that slight cooling of deceased kidney donors can

...

 
BRIEF-Galenica: Vifor Fresenius Medical Care Renal Pharma enters into ... - Reuters PDF Print

BRIEF-Galenica: Vifor Fresenius Medical Care Renal Pharma enters into ...
Reuters
BRIEF-Galenica: Vifor Fresenius Medical Care Renal Pharma enters into partnership with Relypsa. Aug 11 Galenica AG : * Vifor Fresenius Medical Care Renal Pharma enters into partnership with Relypsa to commercialise patiromer FOS Source text ...

...

 
<< Start < Prev 21 22 23 24 25 26 27 28 29 30 Next > End >>

Page 29 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.